<DOC>
	<DOCNO>NCT02467751</DOCNO>
	<brief_summary>Metabolic profile woman different body composition polycystic ovary syndrome .</brief_summary>
	<brief_title>Women With Polycystic Ovary Syndrome ( PCOS )</brief_title>
	<detailed_description>Will perform case-control study woman Polycystic Ovary Syndrome , accord Rotterdam criterion body mass index 18 29.9 . The control group consist woman without Polycystic Ovary Syndrome , body mass index 18 29.9 comorbidities . In group collect anthropometric data age , weight , height , waist circumference blood pressure . Exams request : metabolic profile ( total cholesterol ( mg/dL ) fraction , triglyceride ( mg/dL ) , blood count , liver function ( U/L ) classical glycemic index ( mg/dL ) ; hormonal profile - insulin ( uIU/ml ) , luteinizing hormone ( IU/L ) , follicle stimulate hormone ( IU/L ) , thyreostimulating hormone ( uIU/ML ) , total free testosterone ( ng/ml ) , 17-hydroxyprogesterone ( ng/ml ) , dehydroepiandrosterone ( ng/ml ) , prolactin ( ug/ml ) . Body composition ( BMI ) perform absorption technique two low energy beam emit X-ray - full body densitometry ( DEXA ) . Expected result : To evaluate visceral fat truncal patient diagnosis Polycystic Ovary Syndrome without obesity .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<criteria>Polycystic Ovary Syndrome , body mass index 18 29.9 , without contraceptive use . Hypothyroidism , hyperprolactinaemia ( define serum prolactin level great 25 ng/mL ) Cushing 's syndrome Nonclassical congenital adrenal hyperplasia ( define serum 17hydroxyprogesterone level great 1.2 5.2 ng/mL follicular luteal phase , respectively ) current previous ( within last three month ) use oral contraceptive hormonal Antidiabetic antiobesity drug .</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>